$72 Million is the total value of Qiming U.S. Ventures Management, LLC's 7 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ICOSAVAX INC | $20,114,000 | -18.6% | 3,510,228 | 0.0% | 27.92% | +20.2% | ||
| TALS | TALARIS THERAPEUTICS INC | $13,226,000 | -54.2% | 2,932,606 | 0.0% | 18.36% | -32.3% | |
| JASPER THERAPEUTICS INC | $11,296,000 | -45.6% | 5,852,982 | 0.0% | 15.68% | -19.7% | ||
| VENTYX BIOSCIENCES INC | $11,133,000 | -9.9% | 910,306 | 0.0% | 15.45% | +33.1% | ||
| KZR | KEZAR LIFE SCIENCES INC | $6,853,000 | -50.2% | 828,711 | 0.0% | 9.51% | -26.5% | |
| New | HILLEVAX INC | $6,109,000 | – | 558,923 | +100.0% | 8.48% | – | |
| ELEV | ELEVATION ONCOLOGY INC | $3,318,000 | -44.5% | 2,370,142 | 0.0% | 4.60% | -17.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-07-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICOSAVAX INC | 8 | Q3 2023 | 37.0% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 37.8% |
| TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
| JASPER THERAPEUTICS INC | 8 | Q3 2023 | 21.1% |
| KEZAR LIFE SCIENCES INC | 8 | Q3 2023 | 12.9% |
| ELEVATION ONCOLOGY INC | 8 | Q3 2023 | 6.6% |
| HILLEVAX INC | 6 | Q3 2023 | 13.9% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-24 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-07-22 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.